The BCR/ABL-inhibitors Imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

International Journal of Cancer

Volumn 127, Issue 9, 2010, Pages 2119-2128

  Salih, Julia ^a   Hilpert, Julia ^a   Placke, Theresa ^a   Grnebach, Frank ^a   Steinle, Alexander ^b   Salih, Helmut Rainer ^a   Krusch, Matthias ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

chronic myeloid leukemia; Dasatinib; Imatinib; Nilotinib; NK cells

Indexed keywords

BCR ABL PROTEIN; CD16 ANTIGEN; CD56 ANTIGEN; DASATINIB; GAMMA INTERFERON; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; NATURAL KILLER CELL RECEPTOR NKG2D; NILOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ALUMINUM SILICATE; ANTINEOPLASTIC AGENT; HLA ANTIGEN CLASS 1; MICA; MICB ANTIGEN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; CELL DEATH; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IMMUNOSURVEILLANCE; INTRACELLULAR SIGNALING; LEUKEMIA CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION; CELL STRAIN K 562; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PRENATAL DEVELOPMENT; TUMOR CELL LINE;

ALUMINUM SILICATES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DOWN-REGULATION; FUSION PROTEINS, BCR-ABL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON-GAMMA; K562 CELLS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES; THIAZOLES;

EID: 77956634317     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25233     Document Type: Article

References (38)

1. Druker BJ,. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112: 4808 -17.
2. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935 -42.
3. O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, Rudoltz M, Filian J, Gathmann I, Druker BJ, Larson RA,. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with Imatinib (IM). ASH Annu Meet Abstr 2008; 112: 186.
4. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD,. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7: 345 -56.
5. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542 -51.
6. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531 -41.
7. Hantschel O, Rix U, Superti-Furga G,. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008; 49: 615 -19.
8. Mannaioni PF, Di Bello MG, Masini E,. Platelets and inflammation: role of platelet-derived growth factor, adhesion molecules and histamine. Inflamm Res 1997; 46: 4 -18.
9. Appel S, Balabanov S, Brummendorf TH, Brossart P,. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells 2005; 23: 1082 -8.
10. Chen J, Schmitt A, Chen B, Rojewski M, Rubeler V, Fei F, Yu Y, Yu X, Ringhoffer M, von Harsdorf S, Greiner J, Gotzz M, et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med 2008; 12: 2107 -18.
11. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, Szpurka H, Maciejewski JP,. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111: 1366 -77.
12. Blake SJ, Bruce LA, Fraser CK, Hayball JD, Hughes TP,. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008; 111: 4415 -16.
13. Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD,. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp Hematol 2009; 37: 256 -65.
14. Savani BN, Mielke S, Adams S, Uribe M, Rezvani K, Yong AS, Zeilah J, Kurlander R, Srinivasan R, Childs R, Hensel N, Barrett AJ,. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 2007; 21: 2145 -52.
15. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A,. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097 -100.
16. Bacher U, Zander AR, Haferlach T, Schnittger S, Fehse B, Kroger N,. Minimal residual disease diagnostics in myeloid malignancies in the post transplant period. Bone Marrow Transplant 2008; 42: 145 -57.
17. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A,. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102: 1389 -96.
18. Baltz KM, Krusch M, Bringmann A, Brossart P, Mayer F, Kloss M, Baessler T, Kumbier I, Peterfi A, Kupka S, Kroeber S, Menzel D, et al. Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J 2007; 21: 2442 -54.
19. Baessler T, Krusch M, Schmiedel BJ, Kloss M, Baltz KM, Wacker A, Schmetzer HM, Salih HR,. Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res 2009; 69: 1037 -45.
20. Jiang K, Zhong B, Gilvary DL, Corliss BC, Hong-Geller E, Wei S, Djeu JY,. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat Immunol 2000; 1: 419 -25.
21. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S,. Functions of natural killer cells. Nat Immunol 2008; 9: 503 -10.
22. Lanier LL,. NK cell recognition. Annu Rev Immunol 2005; 23: 225 -74.
23. Boissel N, Rea D, Tieng V, Dulphy N, Brun M, Cayuela JM, Rousselot P, Tamouza R, Le Bouteiller P, Mahon FX, Steinle A, Charron D, et al. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol 2006; 176: 5108 -16.
24. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P, Capdeville R,. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22: 935 -42.
25. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, Kocher T, Superti-Furga G,. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110: 4055 -63.
26. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH,. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165 -71.
27. Rabinowich H, Herberman RB, Whiteside TL,. Differential effects of IL12 and IL2 on expression and function of cellular adhesion molecules on purified human natural killer cells. Cell Immunol 1993; 152: 481 -98.
28. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K, Caligiuri MA,. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994; 180: 1395 -403.
29. Cooper MA, Fehniger TA, Caligiuri MA,. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633 -40.
30. Wei S, Gamero AM, Liu JH, Daulton AA, Valkov NI, Trapani JA, Larner AC, Weber MJ, Djeu JY,. Control of lytic function by mitogen-activated protein kinase/extracellular regulatory kinase 2 (ERK2) in a human natural killer cell line: identification of perforin and granzyme B mobilization by functional ERK2. J Exp Med 1998; 187: 1753 -65.
31. Djeu JY, Jiang K, Wei S,. A view to a kill: signals triggering cytotoxicity. Clin Cancer Res 2002; 8: 636 -40.
32. Mainiero F, Gismondi A, Soriani A, Cippitelli M, Palmieri G, Jacobelli J, Piccoli M, Frati L, Santoni A,. Integrin-mediated ras-extracellular regulated kinase (ERK) signaling regulates interferon γ production in human natural killer cells. J Exp Med 1998; 188: 1267 -75.
33. Chuang SS, Kumaresan PR, Mathew PA,. 2B4 (CD244)-mediated activation of cytotoxicity and IFN-γ release in human NK cells involves distinct pathways. J Immunol 2001; 167: 6210 -16.
34. Lieberman LA, Hunter CA,. Regulatory pathways involved in the infection-induced production of IFN-γ by NK cells. Microbes Infect 2002; 4: 1531 -8.
35. Kim N, Saudemont A, Webb L, Camps M, Ruckle T, Hirsch E, Turner M, Colucci F,. The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion. Blood 2007; 110: 3202 -8.
36. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Hoglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009; 23: 1398 -405.
37. Copland M, Fraser AR, Harrison SJ, Holyoake TL,. Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia. Cancer Immunol Immunother 2005; 54: 297 -306.
38. Yong AS, Keyvanfar K, Hensel N, Eniafe R, Savani BN, Berg M, Lundqvist A, Adams S, Sloand EM, Goldman JM, Childs R, Barrett AJ,. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 2009; 113: 875 -82.